We are developing KVD900 as an on-demand therapy for acute HAE attacks and reported positive results in a Phase 2 trial. KVD824 is in development for prophylactic treatment of HAE with a Phase 2 expected to initiate in the second quarter of 2021. Our oral Factor XIIa inhibitor program represents a new generation of therapies that may further improve the treatment of HAE for patients. In DME, an intravitreally administered plasma kallikrein inhibitor called KVD001, completed a Phase 2 clinical trial in 2019.
We have an R&D team with an established track record in the pharmaceutical development of small molecule protease inhibitors, world-leading expertise in the role of plasma kallikrein in disease, and a management team with the capability to bring small molecules through the clinic to commercialization.
Our offices and labs are in Cambridge, MA and Salisbury, UK.